IP Library Granted Patent US 8,846,076
Granted Patent B2
US 8,846,076 · App. 13/682,085 · Granted Sep 30, 2014

Hemostatic sponge

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,076
App. No.
13/682,085
Granted
Sep 30, 2014
Kind
B2
Abstract

A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Claims (34)

1. A hemostatic sponge comprising:

a substrate comprising a sponge matrix;

a kaolin material applied to the substrate; and

a glycerol binder configured to retain the kaolin material to the sponge matrix;

wherein the hemostatic sponge is subjected to a drying process after the kaolin material is applied to the sponge matrix; and

wherein the sponge is configured such that when treating a bleeding wound, application of the sponge is capable of causing blood to be absorbed into the sponge matrix of the substrate and causing at least a portion of the kaolin material to come into contact with blood to assist in accelerating clotting.

2. The hemostatic sponge of claim 1 , further comprising a pharmaceutically-active composition selected from the group consisting of antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics, antihistamines, compounds containing silver or copper ions, and combinations of the foregoing compositions.

3. The hemostatic sponge of claim 1 , wherein the substrate is fabricated from a material selected from the group consisting of cotton, silk, wool, plastic, cellulose, rayon, polyester, and combinations of the foregoing.

4. The hemostatic sponge of claim 1 , wherein the substrate is flexible to allow the substrate to form to a shape of the bleeding wound and to retain a shape of the bleeding wound.

5. The hemostatic sponge of claim 1 , further comprising a release agent disposed on a surface of the hemostatic sponge.

6. The hemostatic sponge of claim 5 , wherein the release agent is selected from the group consisting of polyvinyl alcohol, glycerol, silicone, carboxymethyl cellulose, and gelatinized starch.

7. The hemostatic sponge of claim 1 , wherein the kaolin material comprises particles having diameters of less than about 0.2 mm.

8. The hemostatic sponge of claim 1 , wherein the glycerol binder is applied to the substrate by a spraying process.

9. The hemostatic sponge of claim 1 , wherein the glycerol binder and the kaolin material are applied to the substrate by a spraying process.

10. The hemostatic sponge of claim 1 , wherein the glycerol binder is applied to the substrate by immersing the substrate in a liquid comprising the glycerol binder.

11. The hemostatic sponge of claim 1 , wherein the glycerol binder and the kaolin material are applied to the substrate by immersing the substrate in a liquid comprising the glycerol binder and the kaolin material.

12. A hemostatic sponge comprising:

a sponge matrix;

a clay material applied to the sponge matrix; and

a calcium alginate binder to bind the clay material to the sponge matrix; and

the sponge is configured such that when treating bleeding, application of the sponge is capable of causing at least a portion of the clay material to come into contact with blood from a bleeding wound to assist in accelerating clotting.

13. The hemostatic sponge of claim 12 , wherein the clay material is selected from the group consisting of attapulgite, bentonite, kaolin, kaolinite, and combinations of the foregoing materials.

14. The hemostatic sponge of claim 12 , further comprising a pharmaceutically-active composition selected from the group consisting of antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics, antihistamines, compounds containing silver or copper ions, and combinations of the foregoing compositions.

15. The hemostatic sponge of claim 12 , wherein the sponge matrix is fabricated from a material selected from the group consisting of cotton, silk, wool, plastic, cellulose, rayon, polyester, and combinations of the foregoing.

16. The hemostatic sponge of claim 12 , wherein the sponge matrix is flexible to allow the sponge matrix to form to a shape of the bleeding wound and to retain the shape of the bleeding wound.

17. The hemostatic sponge of claim 12 , further comprising a release agent disposed on the hemostatic sponge.

18. The hemostatic sponge of claim 17 , wherein the release agent is selected from the group consisting of polyvinyl alcohol, glycerol, silicone, carboxymethyl cellulose, and gelatinized starch.

19. The hemostatic sponge of claim 12 , wherein the clay material comprises kaolin particles having diameters of less than about 0.2 mm.

20. The hemostatic sponge of claim 19 , wherein the sponge matrix is flexible to allow the substrate to form to and retain the shape of the bleeding wound.

21. A hemostatic device comprising:

a sponge material;

a hemostatic material comprising kaolin; and

a calcium alginate binder applied to the sponge material to bind the hemostatic material to the sponge material, wherein the calcium alginate binder and the hemostatic material are applied by spraying or immersion; and

wherein the device is configured such that when treating bleeding, application of the device is capable of causing blood to be absorbed within the device and of causing at least a portion of the hemostatic material to come into contact with blood to assist in accelerating clotting.

Assignments (19)
SECURITY INTEREST Recorded Mar 1, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066723/0376 →
CHANGE OF NAME Recorded Feb 29, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066836/0737 →
MERGER Recorded Feb 29, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066707/0695 →
MERGER Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066621/0946 →
CHANGE OF NAME Recorded Feb 16, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066621/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066616/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066434/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: Z-MEDICA, LLC
To: TELEFLEX LIFE SCIENCES LIMITED
Reel/Frame 058740/0387 →
SECURITY INTEREST Recorded Mar 2, 2021
From: Z-MEDICA, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055455/0099 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2021
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: Z-MEDICA, LLC
Reel/Frame 054832/0770 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INADVERTENT OMISSION OF APPLICATION NO. 14/185873 FROM THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 044151 FRAME: 0282. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 22, 2020
From: MADISON CAPITAL FUNDING LLC
To: Z-MEDICA, LLC
Reel/Frame 054882/0904 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 035308/0704 Recorded Oct 9, 2017
From: MADISON CAPITAL FUNDING LLC
To: Z-MEDICA, LLC
Reel/Frame 044151/0282 →
SECURITY INTEREST Recorded Sep 29, 2017
From: Z-MEDICA, LLC
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 043738/0690 →
RELEASE AND REASSIGNMENT Recorded Apr 9, 2015
From: ABACUS FINANCE GROUP, LLC
To: Z-MEDICA, LLC
Reel/Frame 035392/0368 →
SECURITY INTEREST Recorded Apr 1, 2015
From: Z-MEDICA, LLC
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 035308/0704 →
MERGER Recorded Apr 1, 2015
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 035353/0423 →
MERGER Recorded Mar 31, 2015
From: Z-MEDICA CORPORATION
To: Z-MEDICA, LLC
Reel/Frame 035300/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2015
From: BASADONNA, GIACOMO; HURSEY, FRANCIS X
To: Z-MEDICA CORPORATION
Reel/Frame 035300/0762 →
SECURITY INTEREST Recorded May 21, 2014
From: Z-MEDICA, LLC
To: ABACUS FINANCE GROUP, LLC, AS AGENT
Reel/Frame 032981/0784 →